72 related articles for article (PubMed ID: 21566913)
1. The role of histopathologic subtyping in predicting neurologic complications in small-cell lung-cancer.
Vanoosterhout A; Thunnissen F; Volovics A; Vandenpol M; Tenvelde G; Twijnstra A
Int J Oncol; 1994 Jan; 4(1):201-5. PubMed ID: 21566913
[TBL] [Abstract][Full Text] [Related]
2. The role of the histologic subclassification of tumor cells in patients with small cell carcinoma of the lung and central nervous system metastases.
Twijnstra A; Thunnissen FB; Lassouw G; Volovics A; Ten Velde GP
Cancer; 1990 Apr; 65(8):1812-5. PubMed ID: 2156606
[TBL] [Abstract][Full Text] [Related]
3. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study.
van Oosterhout AG; van de Pol M; ten Velde GP; Twijnstra A
Cancer; 1996 Apr; 77(8):1434-41. PubMed ID: 8608526
[TBL] [Abstract][Full Text] [Related]
4. Neurologic complications of lung cancer.
Dropcho EJ
Handb Clin Neurol; 2014; 119():335-61. PubMed ID: 24365305
[TBL] [Abstract][Full Text] [Related]
5. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer.
Verschuuren JJ; Perquin M; ten Velde G; De Baets M; Vriesman PB; Twijnstra A
J Neurol Neurosurg Psychiatry; 1999 Sep; 67(3):353-7. PubMed ID: 10449558
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients.
Miura S; Kaira K; Kaira R; Akamatsu H; Ono A; Shukuya T; Tsuya A; Nakamura Y; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
Invest New Drugs; 2015 Jun; 33(3):755-60. PubMed ID: 25846908
[TBL] [Abstract][Full Text] [Related]
7. Histologic changes in small cell lung carcinoma after treatment.
Fushimi H; Kikui M; Morino H; Yamamoto S; Tateishi R; Wada A; Aozasa K; Kotoh K
Cancer; 1996 Jan; 77(2):278-83. PubMed ID: 8625235
[TBL] [Abstract][Full Text] [Related]
8. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
9. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype.
da Cunha Santos G; Lai SW; Saieg MA; Geddie WR; Pintilie M; Tsao MS; Boerner SL; Hwang D
Lung Cancer; 2012 Sep; 77(3):501-6. PubMed ID: 22656670
[TBL] [Abstract][Full Text] [Related]
10. Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification.
Rodriguez EF; Monaco SE; Dacic S
Cancer Cytopathol; 2013 Nov; 121(11):629-37. PubMed ID: 23943235
[TBL] [Abstract][Full Text] [Related]
11. The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.
Sakao Y; Okumura S; Mingyon M; Uehara H; Ishikawa Y; Nakagawa K
J Thorac Oncol; 2011 Mar; 6(3):494-9. PubMed ID: 21266920
[TBL] [Abstract][Full Text] [Related]
12. Histologic transformation of non-small-cell lung cancer in brain metastases.
Jiang M; Zhu X; Han X; Jing H; Han T; Li Q; Ding X
Int J Clin Oncol; 2019 Apr; 24(4):375-384. PubMed ID: 30443811
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer.
Wang X; Jiang R; Li K
Cell Biochem Biophys; 2014 Jul; 69(3):633-40. PubMed ID: 24554485
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?
VanderMeer R; Chambers S; Van Dam A; Cutz JC; Goffin JR; Ellis PM
Curr Oncol; 2015 Aug; 22(4):272-8. PubMed ID: 26300665
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer.
Anderson NE; Rosenblum MK; Graus F; Wiley RG; Posner JB
Neurology; 1988 Sep; 38(9):1391-8. PubMed ID: 2842702
[TBL] [Abstract][Full Text] [Related]
16. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma.
Akslen LA; LiVolsi VA
Cancer; 2000 Apr; 88(8):1902-8. PubMed ID: 10760768
[TBL] [Abstract][Full Text] [Related]
18. Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study.
Gozzard P; Chapman C; Vincent A; Lang B; Maddison P
PLoS One; 2015; 10(11):e0143558. PubMed ID: 26606748
[TBL] [Abstract][Full Text] [Related]
19. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
20. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies.
Lucchinetti CF; Kimmel DW; Lennon VA
Neurology; 1998 Mar; 50(3):652-7. PubMed ID: 9521251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
